FrancophonIA/ELRC3.0 huggingface dataset:
English: Metamizole may reduce the effect of ASA on platelet aggregation when taken concomitantly.
Estonian: Samaaegselt manustatud metamisool võib vähendada ASH toimet trombotsüütide agregatsioonile.
English: If you have any further questions, ask your doctor, or pharmacist.
Estonian: - Kui teil on lisaküsimusi, pidage nõu oma arsti või apteekriga.
English: In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
Estonian: CAPRIE uuringus oli veritsuse üldine esinemissagedus 9,3% nii klopidogreeliga kui ka ASH-ga ravitud patsientidel.
English: • In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Qwave myocardial infarction): The optimal duration of treatment has not been formally established.
Estonian: • ST-segmendi elevatsioonita ägeda koronaarsündroomiga patsientidel (ebastabiilne stenokardia või Q-sakita müokardiinfarkt).
English: What you need to know before you take Clopidogrel/Acetylsalicylic acid Mylan Do not take Clopidogrel/Acetylsalicylic acid Mylan
Estonian: Mida on vaja teada enne Clopidogrel/Acetylsalicylic acid Mylani võtmist
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets contain Allura Red AC which may cause allergic reactions.
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid sisaldavad Allura red AC-d, mis võib põhjustada allergilisi reaktsioone.
English: What Clopidogrel/Acetylsalicylic acid Mylan is and what it is used for What you need to know before you take Clopidogrel/Acetylsalicylic acid Mylan How to take Clopidogrel/Acetylsalicylic acid Mylan Possible side effects
Estonian: 1. Mis ravim on Clopidogrel/Acetylsalicylic acid Mylan ja milleks seda kasutatakse 2. Mida on vaja teada enne Clopidogrel/Acetylsalicylic acid Mylani võtmist 3.
English: Periodic safety update reports (PSURs)
Estonian: • Perioodilised ohutusaruanded
English: A significantly lower exposure to clopidogrel active metabolite and reduced platelet inhibition have been demonstrated in HIV-infected patients treated with ritonavir- or cobicistat-boosted anti-retroviral therapies.
Estonian: HIV-infektsiooniga patsientidel, kes saavad ritonaviiri või kobitsistaadiga võimendatud retroviirusvastast ravi, on ilmnenud oluliselt väiksem klopidogreeli aktiivse metaboliidi ekspositsioon ja väiksem trombotsüütide inhibeerimise määr.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Yellow, oval shaped, biconvex, film-coated tablets, approximately 14.5 mm x 7.4 mm debossed with “CA2” on one side of the tablet and “M” on the other side.
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid Kollased ovaalsed kaksikkumerad õhukese polümeerikattega tabletid, ligikaudu 14,5 mm x 7,4 mm, ühel küljel on pimetrükk „CA2“ ja teisel küljel on „M“.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Pink, oval shaped, biconvex, film-coated tablets, approximately 14.8 mm x 7.8 mm debossed with “CA3” on one side of the tablet and “M” on the other side.
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid Roosad ovaalsed kaksikkumerad õhukese polümeerikattega tabletid, ligikaudu 14,8 mm x 7,8 mm, ühel küljel on pimetrükk „CA3“ ja teisel küljel on „M“.
English: It is unknown whether ASA dose in Clopidogrel/Acetylsalicylic acid Mylan alters fertility.
Estonian: Ei ole teada kas Clopidogrel/Acetylsalicylic acid Mylanis sisalduv ASH annus kahjustab fertiilsust.
English: How to take Clopidogrel/Acetylsalicylic acid Mylan
Estonian: Kuidas Clopidogrel/Acetylsalicylic acid Mylanit võtta
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Mylan should be given as a single daily 75 mg/75 mg dose.
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid Clopidogrel/Acetylsalicylic acid Mylani tuleb manustada ühekordse ööpäevase annusena 75 mg/75 mg.
English: Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia
Estonian: Seedetrakti verejooks, diarröa, kõhuvalu, düspepsia
English: In patients concomitantly receiving nicorandil and NSAIDs including ASA and LAS, there is an increased risk for severe complications such as gastrointestinal ulceration, perforation and haemorrhage (see section 4.4).
Estonian: Patsientidel, kes saavad samaaegset ravi nikorandiili ja mittesteroidsete põletikuvastaste ravimitega, k.a atsetüülsalitsüülhape ja lüsiin-atsetüülsalitsüülhape, on raskete tüsistuste, nt seedetrakti haavandumise, mulgustumise ja verejooksu, risk suurem (vt lõik 4.4).
English: In patients concomitantly receiving nicorandil and NSAIDs including ASA and LAS, there is an increased risk for severe complications such as gastrointestinal ulceration, perforation and haemorrhage (see section 4.5).
Estonian: Patsientidel, kes saavad samaaegset ravi nikorandiili ja mittesteroidsete põletikuvastaste ravimitega, k.a atsetüülsalitsüülhape ja lüsiin-atsetüülsalitsüülhape, on raskete tüsistuste, nt seedetrakti haavandumise, mulgustumise ja verejooksu, risk suurem (vt lõik 4.5).
English: GI undesirable effects including stomach pain, heartburn, nausea, vomiting, and GI bleeding may occur.
Estonian: Võivad tekkida seedetrakti kõrvaltoimed, k.a maovalu, kõrvetised, iiveldus, oksendamine ja gastrointestinaalne veritsus.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets EU/1/19/1395/001 - Cartons of 28 film coated tablets in aluminium blister packs EU/1/19/1395/002 - Cartons of 30 film coated tablets in aluminium blister packs EU/1/19/1395/003 - Cartons of 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/004 - Cartons of 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/005 - Cartons of 100 film coated tablets in HDPE bottle packs
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid EU/1/19/1395/001 - Karp 28 õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/002 - Karp 30 õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/003 - Karp 28 x 1 (üksikannus) õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/004 - Karp 30 x 1 (üksikannus) õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/005 - Karp 100 õhukese polümeerikattega tabletiga HDPE pudelis
English: th month of pregnancy), acetylsalicylic acid should not be given unless clearly necessary.
Estonian: Kuni amenorröa 24. nädalani (raseduse 5. kuu) ei tohi manustada atsetüülsalitsüülhapet, väljaarvatud juhul, kui see on hädavajalik.
English: Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N=6,259) plus ASA (75-325 mg once daily) or ASA alone (N=6,303), (75-325 mg once daily) and other standard therapies.
Estonian: (75...325 mg üks kord ööpäevas) või ainult ASH-ga (N=6303, 75...325 mg üks kord ööpäevas) lisaks standardravile.
English: How to store Clopidogrel/Acetylsalicylic acid Mylan
Estonian: Kuidas Clopidogrel/Acetylsalicylic acid Mylanit säilitada
English: Headache, stomach ulcer, vomiting, nausea, constipation, excessive gas in stomach or intestines, rashes, itching, dizziness, sensation of tingling and numbness.
Estonian: Aeg-ajalt esinevad kõrvaltoimed (võivad tekkida kuni 1 inimesel 100-st): peavalu, maohaavand, oksendamine, iiveldus, kõhukinnisus, gaaside teke maos või sooltes, lööve, sügelus, pearinglus, torkimistunne ja tundetus.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid (ASA).
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid Üks õhukese polümeerikattega tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 100 mg atsetüülsalitsüülhapet (ASH).
English: if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red stools or black stools).
Estonian: • peate teavitama oma arsti, kui teil on plaanis minna kirurgilisele operatsioonile (k.a hambaoperatsioon); kui teil on mao- või kõhuvalu või veritsus maost või sooltest (punane või must väljaheide);
English: Gynaecomastia
Estonian: Valproehape
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets EU/1/19/1395/006 - Cartons of 28 film coated tablets in aluminium blister packs EU/1/19/1395/007 - Cartons of 30 film coated tablets in aluminium blister packs EU/1/19/1395/008 - Cartons of 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/009 - Cartons of 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/010 - Cartons of 100 film coated tablets in HDPE bottle packs
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid EU/1/19/1395/006 - Karp 28 õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/007 - Karp 30 õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/008 - Karp 28 x 1 (üksikannus) õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/009 - Karp 30 x 1 (üksikannus) õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/010 - Karp 100 õhukese polümeerikattega tabletiga HDPE pudelis
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid (ASA).
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid Üks õhukese polümeerikattega tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 75 mg atsetüülsalitsüülhapet (ASH).
English: Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 75 mg of acetylsalicylic acid.
Estonian: Üks tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 75 mg atsetüülsalitsüülhapet.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid clopidogrelum/acidum acetylsalicylicum
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg tablets
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg tabletid
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets are yellow, oval shaped biconvex tablets imprinted with CA2 on one side of the tablet and M on the other side.
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid on kollased ovaalsed kaksikkumerad tabletid, mille ühel küljel on pimetrükk „CA2“ ja teisel küljel on „M“.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg tablets
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg tabletid
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets are pink, oval-shaped biconvex, tablets imprinted with CA3 on one side of the tablet and M on the other side.
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid on roosad ovaalsed kaksikkumerad tabletid, mille ühel küljel on pimetrükk „CA3“ ja teisel küljel on „M“.
English: Each tablet contains 75 mg of clopidogrel (as hydrogen sulphate) and 100 mg of acetylsalicylic acid.
Estonian: Üks tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 100 mg atsetüülsalitsüülhapet.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets clopidogrel/acetylsalicylic acid
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid klopidogreel/atsetüülsalitsüülhape (clopidogrelum/acidum acetylsalicylicum)
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets clopidogrel/acetylsalicylic acid
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid clopidogrelum/acidum acetylsalicylicum
English: Each film-coated tablet contains 75 mg clopidogrel (as hydrogen sulphate) and 100 mg acetylsalicylic acid
Estonian: Üks õhukese polümeerikattega tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 100 mg atsetüülsalitsüülhapet
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Mylan should be given as a single daily 75 mg/100 mg dose
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid Clopidogrel/Acetylsalicylic acid Mylani tuleb manustada ühekordse ööpäevase annusena 75 mg/100 mg.
English: Haematoma
Estonian: Hematuuria
English: Varicella vaccine
Estonian: Omandatud hemofiilia
English: Each film-coated tablet contains 75 mg clopidogrel (as hydrogen sulphate) and 75 mg acetylsalicylic acid.
Estonian: Üks õhukese polümeerikattega tablett sisaldab 75 mg klopidogreeli (vesiniksulfaadina) ja 75 mg atsetüülsalitsüülhapet.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid
English: EU/1/19/1395/001 - 28 film coated tablets in aluminium blister packs EU/1/19/1395/002 - 30 film coated tablets in aluminium blister packs EU/1/19/1395/003 - 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/004 - 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/005 - 100 film coated tablets in HDPE bottle packs
Estonian: EU/1/19/1395/001 - Karp 28 õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/002 - Karp 30 õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/003 - Karp 28 x 1 (üksikannus) õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/004 - Karp 30 x 1 (üksikannus) õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/005 - Karp 100 õhukese polümeerikattega tabletiga HDPE pudelis
English: Anti-retroviral therapies (ART)
Estonian: Retroviirusvastane ravi
English: • Severe hepatic impairment.
Estonian: • ST-segmendi elevatsiooniga äge müokardi infarkt.
English: EU/1/19/1395/006 - 28 film coated tablets in aluminium blister packs EU/1/19/1395/007 - 30 film coated tablets in aluminium blister packs EU/1/19/1395/008 - 28 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/009 - 30 x 1 (unit dose) film coated tablets in aluminium blister packs EU/1/19/1395/010 - 100 film coated tablets in HDPE bottle packs
Estonian: EU/1/19/1395/006 - Karp 28 õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/007 - Karp 30 õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/008 - Karp 28 x 1 (üksikannus) õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/009 - Karp 30 x 1 (üksikannus) õhukese polümeerikattega tabletiga alumiiniumblistris EU/1/19/1395/010 - Karp 100 õhukese polümeerikattega tabletiga HDPE pudelis
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablets Hypromellose
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tabletid Hüpromelloos
English: Some other medicines may influence the use of Clopidogrel/Acetylsalicylic Mylan or vice versa You should specifically tell your doctor if you take
Estonian: Mõned teised ravimid võivad mõjutada Clopidogrel/Acetylsalicylic acid Mylani toimet ja vastupidi.
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablets Hypromellose
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tabletid Hüpromelloos
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg film-coated tablet The active substances are clopidogrel and acetylsalicylic acid.
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/75 mg õhukese polümeerikattega tablett Toimeained on klopidogreel ja atsetüülsalitsüülhape.
English: Valproic acid
Estonian: Naatriumlaurüülsulfaat
English: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg film-coated tablet The active substances are clopidogrel and acetylsalicylic acid.
Estonian: Clopidogrel/Acetylsalicylic acid Mylan 75 mg/100 mg õhukese polümeerikattega tablett Toimeained on klopidogreel ja atsetüülsalitsüülhape.
English: This summary was last updated in 04-2012.
Estonian: Kokkuvõtte viimane uuendus: 04-2012.
English: The patients were mainly of Asian origin and had an average age of 36 years.
Estonian: Patsiendid olid peamiselt Aasia päritolu ja nende keskmine vanus oli 36 eluaastat.
English: None of the patients had been treated with nucleoside analogues before.
Estonian: Ühtegi patsienti ei oldud varem nukleosiidianaloogidega ravitud.
English: If this is not possible, they should take the tablets less often.
Estonian: Kui see ei ole võimalik, tuleb neil võtta tablette harvem.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Sebivo on 24 April 2007.
Estonian: Euroopa Komisjon andis Sebivo müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 24. aprillil
English: The full EPAR for Sebivo can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Sebivo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: EPAR summary for the public telbivudine
Estonian: Kokkuvõte üldsusele telbivudiin
English: Patients with kidney problems should be closely monitored.
Estonian: Neeruprobleemidega patsiente tuleb hoolikalt jälgida.
English: It is available as tablets (600 mg) and as an oral solution (20 mg/ml).
Estonian: Seda turustatakse tablettidena (600 mg) ja suukaudse lahusena (20 mg/ml).
English: Other information about Sebivo
Estonian: Muu teave Sebivo kohta
English: The CHMP decided that Sebivo's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Sebivo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The main measure of effectiveness was the number of patients who had responded to treatment after a year.
Estonian: Efektiivsuse põhinäitaja oli ravivastusega patsientide arv ühe aasta pärast.
English: By stopping the virus making DNA, telbivudine prevents it from multiplying and spreading.
Estonian: Viiruse DNA moodustumise tõkestamisega takistab telbivudiin viiruse paljunemist ja levimist.
English: The patient's blood should be monitored every six months for the presence of DNA from the hepatitis B virus.
Estonian: Iga 6 kuu järel tuleb analüüsida patsiendi verd B-hepatiidi viiruse DNA suhtes.
English: Because creatine phosphokinase is an enzyme that is raised when muscles are damaged, doctors need to monitor all muscle-related side effects closely.
Estonian: Et kreatiinfosfokinaas on ensüüm, mille sisaldus suureneb lihaskahjustuste korral, peab arst jälgima hoolikalt kõiki lihastega seonduvaid kõrvalnähte.
English: What is the risk associated with Sebivo?
Estonian: Mis riskid Sebivoga kaasnevad?
English: Why has Sebivo been approved?
Estonian: Miks Sebivo heaks kiideti?
English: What is Sebivo?
Estonian: Mis on Sebivo?
English: For more information about treatment with Sebivo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Sebivoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sebivo.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The company also presented the results of a study showing that the oral solution produced the same levels of the active substance in the blood as the tablets.
Estonian: Ettevõte esitas ka uuringu tulemused, mis näitasid, et suukaudse lahusega ja tablettidega saavutati toimeaine sama sisaldus veres.
English: Starting treatment with Sebivo should only be considered when it is not possible or appropriate to use an alternative medicine which the hepatitis B virus is less likely to develop resistance to.
Estonian: Sebivo ravi alustamist tuleb kaaluda üksnes siis, kui teisi ravimeid, millele B-hepatiidi viiruse resistentsus on vähem tõenäoline, ei saa kasutada või kui need ei sobi.
English: The most common side effects with Sebivo (seen in between 1 and 10 patients in 100) are dizziness, headache, cough, increased levels of some enzymes in the blood (amylase, lipase, creatine phosphokinase and alanine aminotransferase), diarrhoea, nausea (feeling sick), abdominal pain (stomach ache), skin rash and fatigue (tiredness).
Estonian: Sebivo kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on peapööritus, peavalu, köha, teatud ensüümide (amülaas, lipaas, kreatiinfosfokinaas ja alaniinaminotransferaas) suurenenud sisaldus veres, kõhulahtisus, iiveldus, kõhuvalu, nahalööve ning väsimus.
English: The oral solution can be considered for patients who have difficulty swallowing tablets.
Estonian: Suukaudset lahust tohivad kasutada patsiendid, kellel on tablette raske neelata.
English: A change of treatment should be considered if viral DNA is found.
Estonian: Kui leitakse viiruse DNA-d, tuleb kaaluda ravi muutmist.
English: Sebivo is a medicine that contains the active substance telbivudine.
Estonian: Sebivo on ravim, mis sisaldab toimeainena telbivudiini.
English: Sebivo tablets were compared with lamivudine (another medicine used in chronic hepatitis B) in a twoyear study involving 1,367 patients.
Estonian: Sebivo tablette võrreldi lamivudiiniga (samuti kroonilise B-hepatiidi ravim) 2-aastases uuringus, kus osales 1367 patsienti.
English: This is a summary of the European public assessment report (EPAR) for Sebivo.
Estonian: See on ravimi Sebivo Euroopa avaliku hindamisaruande kokkuvõte.
English: In the HBeAg-negative patients, Sebivo was as effective as lamivudine (75% and 77% responding, respectively).
Estonian: HBeAg-negatiivsete patsientide rühmas oli Sebivo sama efektiivne kui lamivudiin (ravivastus tekkis vastavalt 75% ja 77% patsientidel).
English: What benefit has Sebivo shown during the studies?
Estonian: Milles seisneb uuringute põhjal Sebivo kasulikkus?
English: Patients who have problems with their kidneys may need to take a lower daily dose using the oral solution.
Estonian: Neeruprobleemidega patsientidel võib olla vaja väiksemat annust, kasutades suukaudset lahust.
English: For the full list of all side effects reported with Sebivo, see the package leaflet.
Estonian: Sebivo kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Sebivo must not be used in people who are hypersensitive (allergic) to telbivudine or to any of the other ingredients.
Estonian: Sebivot ei tohi kasutada patsiendid, kes on telbivudiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The results were also calculated separately between ‘HBeAg-positive' patients (infected with the common hepatitis B virus) and ‘HBeAg-negative' patients (infected with a virus that has mutated, leading to a form of chronic hepatitis B that is more difficult to treat).
Estonian: Tulemused arvutati eraldi ka patsientide kohta, kes olid HBeAg-positiivsed (tavalise B-hepatiidi viirusega nakatunud) või HBeAg-negatiivsed (nakatunud muteerunud viirusega, mille tulemusena võib tekkida raskemini ravitav krooniline B-hepatiidi vorm).